source
- Ultragenyx sells second priority review voucher as Biomea shares tumble after oral GLP-1 dataUltragenyx Pharmaceutical, a commercial-stage rare disease company, completed its second sale of a priority review voucher this month. The voucher sale reflects the company's strategy of monetizin…
- Study finds almost 40% of FDA advisory committee meetings in past two decades included members with active industry tiesResearchers examined FDA advisory committee meetings spanning the last 20 years and discovered that nearly 40% of those sessions featured a patient or consumer representative who had active ties to…